コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ultimately drive the pulsatile secretion of gonadotropin-releasing hormone.
2 l basis for a putative role of sbGnRH as the gonadotropin-releasing hormone.
3 to provide an episodic, excitatory drive to gonadotropin-releasing hormone 1 (GnRH) neurons, the syn
6 thalamic neurons that synthesize and release gonadotropin-releasing hormone 1 (GnRH1), but the precis
8 cystokinin (CCK) in the developing olfactory-gonadotropin-releasing hormone-1 (GnRH-1) neuroendocrine
11 asic ovarian sex hormone fluctuation using a gonadotropin-releasing hormone agonist (GnRHa) and evalu
12 rted previously that after 1-year follow up, gonadotropin-releasing hormone agonist (GnRHa) did not p
13 by surgical castration and those who receive gonadotropin-releasing hormone agonist (GnRHa) therapy.
14 nditions: ovarian suppression induced by the gonadotropin-releasing hormone agonist leuprolide acetat
16 umulation increased after treatment with the gonadotropin-releasing hormone agonist leuprolide, which
18 over study, 12 healthy, young males received gonadotropin-releasing hormone agonist treatment 1 month
19 nditions: ovarian suppression induced by the gonadotropin-releasing hormone agonist, leuprolide aceta
20 al women, or premenopausal women receiving a gonadotropin-releasing hormone agonist, with estrogen re
21 nmetastatic disease, intervention group with gonadotropin-releasing hormone agonist-based ADT, contro
25 ntraindication to tamoxifen may be offered a gonadotropin-releasing hormone agonist/antagonist plus a
26 production was achieved with the use of the gonadotropin-releasing-hormone agonist triptorelin, ooph
29 herapies (OR, 4.04 [95% CI, 1.88-8.69]), and gonadotropin-releasing hormone agonists (OR, 1.93 [95% C
30 androgen deprivation therapy in the form of gonadotropin-releasing hormone agonists and newer antago
33 y a combined androgen blockade consisting of gonadotropin-releasing hormone agonists with oral antian
34 er treatments such as surgical oophorectomy, gonadotropin-releasing hormone agonists, chemotherapy-in
35 rized into 1 of 6 mutually exclusive groups: gonadotropin-releasing hormone agonists, oral antiandrog
36 ess of depot leuprolide acetate, a synthetic gonadotropin-releasing hormone analog (GnRH-a), for prot
37 of glucocorticoid replacement, 19.2%; and of gonadotropin-releasing hormone analog therapy, 34.2%.
38 ne [n = 33 835], gonadotropins [n = 57 136], gonadotropin-releasing hormone analogs [n = 38 653], hum
40 rel-releasing intrauterine system (LNG-IUD), gonadotropin-releasing hormone analogues (GnRHa; nafarel
42 n suppression (castration via orchiectomy or gonadotropin-releasing hormone analogues) suppresses cir
44 ikely to be mediated by reduced secretion of gonadotropin-releasing hormone and our results support t
46 onsiveness to the endogenous natural ligand, gonadotropin releasing hormone, and an agonist that is s
48 o the antral stage in both immature mice and gonadotropin releasing hormone antagonist-treated adult
50 (ii) a single subcutaneous injection of the gonadotropin-releasing hormone antagonist (GnRH-A), acyl
52 le-stimulating hormone and administration of gonadotropin-releasing hormone antagonist to prevent pre
53 of short-term castration (1 month) using the gonadotropin-releasing hormone antagonist, Acyline, vers
54 he efficacy and safety of relugolix, an oral gonadotropin-releasing hormone antagonist, as compared w
55 been found for other classes of drugs (e.g., gonadotropin-releasing hormone antagonists, neurokinin r
56 levels are increased somewhat by exposure to gonadotropin-releasing hormone but are not necessarily l
58 17beta-estradiol (E2) regulating release of gonadotropin releasing hormone (GnRH) and luteinizing ho
59 tress index, CSI), women self administered a gonadotropin releasing hormone (GnRH) antagonist for 16
60 zed by absent puberty and infertility due to gonadotropin releasing hormone (GnRH) deficiency, which
61 ntrolled in part by the pulsatile release of gonadotropin releasing hormone (GnRH) from the hypothala
63 stone deacetylases (HDACs) in the control of gonadotropin releasing hormone (GnRH) neuronal developme
64 odulate the central driver of fertility: the gonadotropin releasing hormone (GnRH) neuronal system.
65 gy balance and season, time the awakening of gonadotropin releasing hormone (GnRH) neurons at the ons
66 onadotropic hypogonadism to study effects of gonadotropin releasing hormone (GnRH) neurons on neurona
70 acetate, a synthetic nonapeptide analogue of gonadotropin-releasing hormone (GnRH or LHRH), is the ac
72 a potent and very long acting antagonist of gonadotropin-releasing hormone (GnRH) after subcutaneous
73 mone but apparently normal responsiveness to gonadotropin-releasing hormone (GnRH) agonist and antago
76 bjected to 26 ART treatment cycles receiving gonadotropin-releasing hormone (GnRH) agonists and recom
81 n were on antiandrogens (AA), 26,959 were on gonadotropin-releasing hormone (GnRH) agonists, and 3,74
82 ective randomized trial evaluated the use of gonadotropin-releasing hormone (GnRH) analog triptorelin
87 ted with oocyte meiosis, TGF-beta signaling, gonadotropin-releasing hormone (GnRH) and epidermal grow
89 and controls the synthesis and/or release of gonadotropin-releasing hormone (GnRH) and gonadotropins.
90 ons are thought to regulate the secretion of gonadotropin-releasing hormone (GnRH) and thus coordinat
93 amining the distribution of cells containing gonadotropin-releasing hormone (GnRH) as well as estroge
95 male rat preoptic area (POA), containing the gonadotropin-releasing hormone (GnRH) cell bodies, treat
96 ypothalamic-pituitary-ovarian axis, in which gonadotropin-releasing hormone (GnRH) controls the relea
98 othalamic amenorrhea is a reversible form of gonadotropin-releasing hormone (GnRH) deficiency commonl
103 Individuals with an inherited deficiency in gonadotropin-releasing hormone (GnRH) have impaired sexu
104 action on puberty by stimulating release of gonadotropin-releasing hormone (GnRH) in the hypothalamu
105 levated levels of transcripts for the salmon gonadotropin-releasing hormone (GnRH) in the male telenc
107 that FOXO1 repressed basal transcription and gonadotropin-releasing hormone (GnRH) induction of both
108 amic median eminence (ME) where they release gonadotropin-releasing hormone (GnRH) into a specialized
112 propriate tissue-specific gene expression of gonadotropin-releasing hormone (GnRH) is critical for pu
126 posed to pulsatile, delivery of hypothalamic gonadotropin-releasing hormone (GnRH) leads to a marked
130 (RFRP-3) neurons have been shown to inhibit gonadotropin-releasing hormone (GnRH) neuronal activity
131 a profound influence on the activity of the gonadotropin-releasing hormone (GnRH) neuronal network c
132 isspeptin is a key regulator of hypothalamic gonadotropin-releasing hormone (GnRH) neurons and is ess
134 diol alters both the intrinsic properties of gonadotropin-releasing hormone (GnRH) neurons and synapt
146 sspeptin neurons act cooperatively to excite gonadotropin-releasing hormone (GnRH) neurons during pos
148 al axis is dependent on correct migration of gonadotropin-releasing hormone (GnRH) neurons from the n
149 oductive functioning in mammals depends upon gonadotropin-releasing hormone (GnRH) neurons generating
150 in mice for controlling the activity of the gonadotropin-releasing hormone (GnRH) neurons in vivo to
152 ut from the suprachiasmatic nucleus (SCN) to gonadotropin-releasing hormone (GnRH) neurons is critica
159 n, rostral projections from the AVPV contact gonadotropin-releasing hormone (GnRH) neurons surroundin
160 onstructions and electrophysiology, that the gonadotropin-releasing hormone (GnRH) neurons that contr
161 rculating estradiol on proestrus to activate gonadotropin-releasing hormone (GnRH) neurons that, in t
162 estradiol (E2) regulates the activity of the gonadotropin-releasing hormone (GnRH) neurons through bo
163 nisms through which estradiol (E2) regulates gonadotropin-releasing hormone (GnRH) neurons to control
164 s how nerve terminal Ca(2+) is controlled in gonadotropin-releasing hormone (GnRH) neurons via action
165 peptin regulates reproduction by stimulating gonadotropin-releasing hormone (GnRH) neurons via the ki
167 mice lacking necdin have reduced numbers of gonadotropin-releasing hormone (GnRH) neurons, but the m
168 eactive fibres also abut the preoptic-septal gonadotropin-releasing hormone (GnRH) neurons, suggestin
169 ne hormone secretion, especially that of the gonadotropin-releasing hormone (GnRH) neurons, via neura
170 arcuate nucleus (Arc) provide tonic drive to gonadotropin-releasing hormone (GnRH) neurons, which in
180 yclicity, including long-acting analogues of gonadotropin-releasing hormone (GnRH) or oestradiol (adm
181 Most cells are immunoreactive for either gonadotropin-releasing hormone (GnRH) or RF-amide-like p
184 ty of kisspeptin-10 to elicit the release of gonadotropin-releasing hormone (GnRH) precociously, and
185 genes are expressed under the control of the gonadotropin-releasing hormone (GnRH) promoter has made
186 lth and wellbeing.SIGNIFICANCE STATEMENT The gonadotropin-releasing hormone (GnRH) pulse generator co
193 o and caused cell death in cells bearing the gonadotropin-releasing hormone (GnRH) receptor, we could
194 ion as a measure of information transfer via gonadotropin-releasing hormone (GnRH) receptors (GnRHR)
196 have specialized adaptations associated with gonadotropin-releasing hormone (GnRH) regulation to opti
197 ement during lethargus, by signaling through gonadotropin-releasing hormone (GnRH) related receptors.
199 ance and obesity are associated with reduced gonadotropin-releasing hormone (GnRH) release and infert
200 t the release of kisspeptin, which modulates gonadotropin-releasing hormone (GnRH) release from GnRH
205 of reproduction by brain-secreted pulses of gonadotropin-releasing hormone (GnRH) represents a longs
207 otropic hypogonadism (IHH) due to defects of gonadotropin-releasing hormone (GnRH) secretion and/or a
209 suggests that MKRN3 is acting as a brake on gonadotropin-releasing hormone (GnRH) secretion during c
210 uberty is orchestrated by an augmentation of gonadotropin-releasing hormone (GnRH) secretion from a f
213 in the regulation of pubertal and adulthood gonadotropin-releasing hormone (GnRH) secretion, and mut
219 ic hypogonadism had a measurable response to gonadotropin-releasing hormone (GnRH) stimulation, sugge
223 lmann syndrome is an inherited deficiency of gonadotropin-releasing hormone (GnRH) that is characteri
224 rmal puberty promotes the central release of gonadotropin-releasing hormone (GnRH) that, in turn, lea
225 revealed that IKK-beta and NF-kappaB inhibit gonadotropin-releasing hormone (GnRH) to mediate ageing-
227 itary gonadotropin hormones are regulated by gonadotropin-releasing hormone (GnRH) via MAPK signaling
228 duce ciliated neurons that express genes for gonadotropin-releasing hormone (GnRH), a G-protein-coupl
229 ) designed to express an antibody that binds gonadotropin-releasing hormone (GnRH), a master regulato
230 and negative modulators drives secretion of gonadotropin-releasing hormone (GnRH), a neuropeptide th
231 (MCH), thyrotropin-releasing hormone (TRH), gonadotropin-releasing hormone (GnRH), and kisspeptin.
232 brain controls fertility through release of gonadotropin-releasing hormone (GnRH), but the mechanism
233 under the control of pulsatile hypothalamic gonadotropin-releasing hormone (GnRH), is essential for
235 pite of the fact that hypothalamic levels of gonadotropin-releasing hormone (GnRH), pituitary release
236 sprouting in hypothalamic neurons secreting gonadotropin-releasing hormone (GnRH), the neuropeptide
237 blished that hypothalamic neurons, including gonadotropin-releasing hormone (GnRH), VP, OT, beta-endo
239 ndent upon the appropriate neurosecretion of gonadotropin-releasing hormone (GnRH), yet the endogenou
242 lamic-pituitary-gonadal axis is dependent on gonadotropin-releasing hormone (GNRH)-stimulated synthes
252 rmone-releasing hormone (LHRH, also known as gonadotropin-releasing hormone [GnRH]), a key neurohormo
253 e reproduction requires pulsatile release of gonadotropin-releasing hormone (GnRH1) from the hypothal
254 In mammals, the receptor of the neuropeptide gonadotropin-releasing hormone (GnRHR) is unique among t
255 basis of selectivity of naturally occurring gonadotropin-releasing hormones (GnRHs) from different s
257 r fibers were observed in close proximity to gonadotropin-releasing hormone-I, dopamine, beta-endorph
258 ing hormone-I, dopamine, beta-endorphin, and gonadotropin-releasing hormone-II neurons in the preopti
259 a neuropeptide homologous to the vertebrate gonadotropin-releasing hormone, is downregulated as work
260 ty and infertility as a result of defects in gonadotropin-releasing hormone neuron development or fun
261 st gonadotropin responses, suggesting normal gonadotropin-releasing hormone neuronal and gonadotrope
263 se neurons also precede the emergence of the gonadotropin-releasing hormone neurons and ensheathing g
264 lamic nucleus and send axonal projections to gonadotropin-releasing hormone neurons and regulate repr
266 Notably, TRPC1 suppressed the migration of gonadotropin-releasing hormone neurons without affecting
267 Z formed appositions with orexin neurons and gonadotropin-releasing hormone neurons, two cell populat
268 sspeptin neurons relay estradiol feedback to gonadotropin-releasing hormone neurons, which regulate t
270 ed hypothalamic cells and immortalized GnRH (gonadotropin-releasing hormone) neurons (GT1-7 cells) tr
271 g hormone, growth hormone-releasing hormone, gonadotropin-releasing hormone, oxytocin, somatostatin,
272 cant relation between the number of doses of gonadotropin-releasing hormone received during the 12 mo
274 ere designed and synthesized as potent human gonadotropin releasing hormone receptor antagonists.
276 in-conjugated gold nanorods (gGNRs) promotes gonadotropin releasing hormone receptor-mediated interna
277 eptide agonists and antagonists of the human gonadotropin-releasing hormone receptor (GnRH-R) are wid
281 on in pedigree 1 and a compound heterozygous gonadotropin-releasing hormone receptor (GNRHR) mutation
282 icipate in partitioning mutant conformers of gonadotropin-releasing hormone receptor (GnRHR), a G pro
283 mines bearing a butyric acid as potent human gonadotropin-releasing hormone receptor (hGnRH-R) antago
284 oral contraceptives/antagonization of human gonadotropin-releasing hormone receptor [hGnRH-R] activi
285 s capable of rescuing the activity of mutant gonadotropin-releasing hormone receptor or GnRHR which,
286 he C-terminal domains of either GluR1 or the gonadotropin-releasing hormone receptor permits efficien
288 regulation (reduced pituitary sensitivity to gonadotropin-releasing hormone), reduced conception rate
289 oter activity, highlighting a role of SET in gonadotropin-releasing hormone regulation of gene expres
290 from the Kiss1 promoter disrupted pulsatile gonadotropin-releasing hormone release, delayed puberty
293 ns, suggesting sensitization of the NKB-NK3R-gonadotropin-releasing hormone signaling pathway under m
295 lular: oxytocin, vasopressin; parvicellular: gonadotropin-releasing hormone, somatostatin, thyrotropi
296 androgen receptors, and by the hypothalamic gonadotropin-releasing hormone through activation of PKA
297 olic, and other factors control secretion of gonadotropin-releasing hormone to determine initiation o
298 uires the pulsatile, coordinated delivery of gonadotropin-releasing hormone to the pituitary and the
300 uctive function requires timely secretion of gonadotropin-releasing hormone, which is controlled by a